← Patent-cliff monitor small molecule HETLIOZ LQ TASIMELTEON
Loss of exclusivity February 2041 latest FDA-listed patent expiry
Drug detail Brand name HETLIOZ LQ Active ingredient TASIMELTEON Strength 4MG/ML Dosage form SUSPENSION Route ORAL Modality Small molecule FDA approval December 2020 Marketing status RX
Listed patents Patent Expires Type 11759446 February 2041 use U-3003 11202770 December 2040 product 12447141 December 2040 use U-3003 11266622 August 2035 use U-3003 10179119 August 2035 use U-3003 10376487 July 2035 use U-3007 11760740 February 2035 substance, product 12049457 February 2035 substance, product 10829465 February 2035 substance, product 10071977 February 2035 substance, product 11566011 February 2035 substance, product 11786502 October 2034 use U-3007 11141400 October 2034 use U-3007 10610511 October 2034 use U-3007 9730910 May 2034 use U-3005 11918556 April 2033 use U-3342 11826339 January 2033 use U-3342 10149829 January 2033 use U-3006 11285129 January 2033 use U-3342 10980770 January 2033 use U-3106 10610510 January 2033 use U-3009 9539234 January 2033 use U-3004 11918557 January 2033 use U-3003 12201604 January 2033 use U-3003 11633377 January 2033 use U-3003 11833130 January 2033 use U-3003 11850229 January 2033 use U-3342
Regulatory exclusivity Code Expires ODE-329 December 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.